Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis:a single-center,prospective study in China  

作　　者：Yihui Chen Qiaozhi Cao Cong Peng Bingjing Zhou Yu Jiang Xiang Chen Jie Li 

机构地区：[1]Department of Dermatology,Xiangya Hospital,Central South University,Changsha,410008,China [2]Hunan Key Laboratory of Skin Cancer and Psoriasis,Xiangya Hospital,Central South University,Changsha,410008,China [3]National Clinical Research Center for Geriatric Disorders,Xiangya Hospital,Central South University,Changsha,410008,China [4]Furong Laboratory,Changsha,410008,China

出　　处：《Frontiers of Medicine》2024年第4期752-756,共5页医学前沿（英文版）

基　　金：approved by the Ethics Committee of Central South University(ethics approval number:202212806);registered with the Chinese Clinical Trials Registry(chictr.org.cn,registration number:ChiCTR2300076625).

摘　　要：Dear Editor,Upadacitinib and abrocitiniboareselective,smallmolecule Janus kinase 1(JAK1)inhibitors approved in China for the treatment of moderate-to-severe atopic dermatitis(AD)[1].The favorable efficacy and tolerable safety of upadacitinib and abrocitinib have been determined in several clinical trials[2-5].However,realworld data,especially in Asian populations,are scant.Therefore,we conducted a prospective,24-week,real-life observational study to assess the effectiveness and safety of abrocitinib and upadacitinib for the treatment of moderate-to-severe AD in a Chinese patient cohort.Ninety patients with moderate-to-severe AD(IGA score 3-4)in the Department of Dermatology.

关 键 词：DERMATITIS PROSPECTIVE TREATMENT 

分 类 号：R75[医药卫生—皮肤病学与性病学]